Nedocromil sodium inhibits canine adenovirus bronchiolitis in beagle dogs

K. A. Anderson, R. J. Lemen, H. Chen, Robert Clark Lantz, M. L. Witten, D. E. Bice, B. A. Muggenburg

Research output: Contribution to journalArticle

Abstract

Nedocromil sodium is a non-steroidal, anti-inflammatory drug used to control asthmatic attacks. Our hypothesis is that nedocromil sodium inhibits viral induced airway inflammation, a common trigger of asthma. We nebulized nedocromil sodium to beagle dogs (n=10, ages, mean ± SEM, 149±13 days) before and after inoculation with canine adenovirus type 2 (CAV2). Controls (n=10) received saline aerosols and were either infected with CAV2 (Sal/CAV2, n=7, ages, 140±11 days) or were not infected (Sal/Sal, n=3, 143±0 days). All dogs were anesthetized with choralose (80 mg/kg,i.v.), intubated and mechanically ventilated. Pulmonary function and bronchoalveolar lavage (BAL) were performed using standard techniques. The percent of infected bronchioles was quantitated, by two trained observers blinded to the study group, as the number of inflamed airways of 40 examined bronchioles times 100 for each dog. In our past studies, acute CAV2 infections were associated with bronchial hyperresponsiveness and bronchiolitis in beagle dogs. Nedocromil-treated dogs, however, had significantly (p<0.05) less mucosal inflammation (mean ± SEM, 39 ± 5 %), epithelial denudation (mean ± SEM, 36 ± 5 %), and BAL neutrophilia (mean ± SEM, 11±3) compared to Sal/CAV2 (mean ± SEM, 51± 6 %, 57±4 %, and 33±8 %, respectively). We conclude that pre-treatment with nedocromil sodium aerosols attenuates CAV2 induced airway inflammation in dogs.

Original languageEnglish (US)
JournalJournal of Investigative Medicine
Volume47
Issue number2
StatePublished - Feb 1999
Externally publishedYes

Fingerprint

Canine Adenoviruses
Nedocromil
Bronchiolitis
Dogs
Scanning electron microscopy
Bronchoalveolar Lavage
Bronchioles
Aerosols
Inflammation
Adenoviridae Infections
Anti-Inflammatory Agents
Asthma
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Anderson, K. A., Lemen, R. J., Chen, H., Lantz, R. C., Witten, M. L., Bice, D. E., & Muggenburg, B. A. (1999). Nedocromil sodium inhibits canine adenovirus bronchiolitis in beagle dogs. Journal of Investigative Medicine, 47(2).

Nedocromil sodium inhibits canine adenovirus bronchiolitis in beagle dogs. / Anderson, K. A.; Lemen, R. J.; Chen, H.; Lantz, Robert Clark; Witten, M. L.; Bice, D. E.; Muggenburg, B. A.

In: Journal of Investigative Medicine, Vol. 47, No. 2, 02.1999.

Research output: Contribution to journalArticle

Anderson, KA, Lemen, RJ, Chen, H, Lantz, RC, Witten, ML, Bice, DE & Muggenburg, BA 1999, 'Nedocromil sodium inhibits canine adenovirus bronchiolitis in beagle dogs', Journal of Investigative Medicine, vol. 47, no. 2.
Anderson, K. A. ; Lemen, R. J. ; Chen, H. ; Lantz, Robert Clark ; Witten, M. L. ; Bice, D. E. ; Muggenburg, B. A. / Nedocromil sodium inhibits canine adenovirus bronchiolitis in beagle dogs. In: Journal of Investigative Medicine. 1999 ; Vol. 47, No. 2.
@article{c13f8a88285a4832a0222ccde9ae5b6e,
title = "Nedocromil sodium inhibits canine adenovirus bronchiolitis in beagle dogs",
abstract = "Nedocromil sodium is a non-steroidal, anti-inflammatory drug used to control asthmatic attacks. Our hypothesis is that nedocromil sodium inhibits viral induced airway inflammation, a common trigger of asthma. We nebulized nedocromil sodium to beagle dogs (n=10, ages, mean ± SEM, 149±13 days) before and after inoculation with canine adenovirus type 2 (CAV2). Controls (n=10) received saline aerosols and were either infected with CAV2 (Sal/CAV2, n=7, ages, 140±11 days) or were not infected (Sal/Sal, n=3, 143±0 days). All dogs were anesthetized with choralose (80 mg/kg,i.v.), intubated and mechanically ventilated. Pulmonary function and bronchoalveolar lavage (BAL) were performed using standard techniques. The percent of infected bronchioles was quantitated, by two trained observers blinded to the study group, as the number of inflamed airways of 40 examined bronchioles times 100 for each dog. In our past studies, acute CAV2 infections were associated with bronchial hyperresponsiveness and bronchiolitis in beagle dogs. Nedocromil-treated dogs, however, had significantly (p<0.05) less mucosal inflammation (mean ± SEM, 39 ± 5 {\%}), epithelial denudation (mean ± SEM, 36 ± 5 {\%}), and BAL neutrophilia (mean ± SEM, 11±3) compared to Sal/CAV2 (mean ± SEM, 51± 6 {\%}, 57±4 {\%}, and 33±8 {\%}, respectively). We conclude that pre-treatment with nedocromil sodium aerosols attenuates CAV2 induced airway inflammation in dogs.",
author = "Anderson, {K. A.} and Lemen, {R. J.} and H. Chen and Lantz, {Robert Clark} and Witten, {M. L.} and Bice, {D. E.} and Muggenburg, {B. A.}",
year = "1999",
month = "2",
language = "English (US)",
volume = "47",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Nedocromil sodium inhibits canine adenovirus bronchiolitis in beagle dogs

AU - Anderson, K. A.

AU - Lemen, R. J.

AU - Chen, H.

AU - Lantz, Robert Clark

AU - Witten, M. L.

AU - Bice, D. E.

AU - Muggenburg, B. A.

PY - 1999/2

Y1 - 1999/2

N2 - Nedocromil sodium is a non-steroidal, anti-inflammatory drug used to control asthmatic attacks. Our hypothesis is that nedocromil sodium inhibits viral induced airway inflammation, a common trigger of asthma. We nebulized nedocromil sodium to beagle dogs (n=10, ages, mean ± SEM, 149±13 days) before and after inoculation with canine adenovirus type 2 (CAV2). Controls (n=10) received saline aerosols and were either infected with CAV2 (Sal/CAV2, n=7, ages, 140±11 days) or were not infected (Sal/Sal, n=3, 143±0 days). All dogs were anesthetized with choralose (80 mg/kg,i.v.), intubated and mechanically ventilated. Pulmonary function and bronchoalveolar lavage (BAL) were performed using standard techniques. The percent of infected bronchioles was quantitated, by two trained observers blinded to the study group, as the number of inflamed airways of 40 examined bronchioles times 100 for each dog. In our past studies, acute CAV2 infections were associated with bronchial hyperresponsiveness and bronchiolitis in beagle dogs. Nedocromil-treated dogs, however, had significantly (p<0.05) less mucosal inflammation (mean ± SEM, 39 ± 5 %), epithelial denudation (mean ± SEM, 36 ± 5 %), and BAL neutrophilia (mean ± SEM, 11±3) compared to Sal/CAV2 (mean ± SEM, 51± 6 %, 57±4 %, and 33±8 %, respectively). We conclude that pre-treatment with nedocromil sodium aerosols attenuates CAV2 induced airway inflammation in dogs.

AB - Nedocromil sodium is a non-steroidal, anti-inflammatory drug used to control asthmatic attacks. Our hypothesis is that nedocromil sodium inhibits viral induced airway inflammation, a common trigger of asthma. We nebulized nedocromil sodium to beagle dogs (n=10, ages, mean ± SEM, 149±13 days) before and after inoculation with canine adenovirus type 2 (CAV2). Controls (n=10) received saline aerosols and were either infected with CAV2 (Sal/CAV2, n=7, ages, 140±11 days) or were not infected (Sal/Sal, n=3, 143±0 days). All dogs were anesthetized with choralose (80 mg/kg,i.v.), intubated and mechanically ventilated. Pulmonary function and bronchoalveolar lavage (BAL) were performed using standard techniques. The percent of infected bronchioles was quantitated, by two trained observers blinded to the study group, as the number of inflamed airways of 40 examined bronchioles times 100 for each dog. In our past studies, acute CAV2 infections were associated with bronchial hyperresponsiveness and bronchiolitis in beagle dogs. Nedocromil-treated dogs, however, had significantly (p<0.05) less mucosal inflammation (mean ± SEM, 39 ± 5 %), epithelial denudation (mean ± SEM, 36 ± 5 %), and BAL neutrophilia (mean ± SEM, 11±3) compared to Sal/CAV2 (mean ± SEM, 51± 6 %, 57±4 %, and 33±8 %, respectively). We conclude that pre-treatment with nedocromil sodium aerosols attenuates CAV2 induced airway inflammation in dogs.

UR - http://www.scopus.com/inward/record.url?scp=33750119734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750119734&partnerID=8YFLogxK

M3 - Article

VL - 47

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 2

ER -